Philip James Wealth Mangement LLC Lowers Stock Position in Gilead Sciences, Inc. $GILD

Philip James Wealth Mangement LLC cut its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 54.5% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 15,913 shares of the biopharmaceutical company’s stock after selling 19,050 shares during the quarter. Philip James Wealth Mangement LLC’s holdings in Gilead Sciences were worth $1,766,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Norges Bank bought a new position in shares of Gilead Sciences in the second quarter worth approximately $2,150,268,000. Ameriprise Financial Inc. lifted its stake in shares of Gilead Sciences by 397.6% during the 2nd quarter. Ameriprise Financial Inc. now owns 6,748,403 shares of the biopharmaceutical company’s stock valued at $748,147,000 after buying an additional 5,392,191 shares in the last quarter. Invesco Ltd. boosted its holdings in Gilead Sciences by 33.5% in the 2nd quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock worth $1,499,098,000 after buying an additional 3,394,330 shares during the period. Assenagon Asset Management S.A. increased its stake in Gilead Sciences by 164.4% in the 3rd quarter. Assenagon Asset Management S.A. now owns 3,489,062 shares of the biopharmaceutical company’s stock worth $387,286,000 after buying an additional 2,169,266 shares in the last quarter. Finally, Kingstone Capital Partners Texas LLC bought a new stake in Gilead Sciences during the second quarter valued at about $238,083,000. Institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Weiss Ratings restated a “buy (b)” rating on shares of Gilead Sciences in a research report on Wednesday, October 8th. Daiwa Capital Markets upped their price target on Gilead Sciences from $128.00 to $129.00 and gave the stock an “outperform” rating in a research note on Thursday, November 13th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $135.00 price objective on shares of Gilead Sciences in a report on Friday, October 31st. Argus boosted their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. Finally, Citigroup upped their target price on shares of Gilead Sciences from $135.00 to $140.00 and gave the stock a “buy” rating in a research report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $133.20.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $122.00, for a total transaction of $366,000.00. Following the transaction, the chief financial officer owned 153,503 shares of the company’s stock, valued at approximately $18,727,366. The trade was a 1.92% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction on Friday, November 28th. The stock was sold at an average price of $125.08, for a total value of $625,400.00. Following the completion of the sale, the director owned 8,920 shares of the company’s stock, valued at approximately $1,115,713.60. This represents a 35.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 136,257 shares of company stock worth $16,855,192. 0.27% of the stock is currently owned by corporate insiders.

Gilead Sciences Trading Up 0.4%

GILD stock opened at $121.10 on Friday. The firm has a fifty day moving average price of $123.27 and a 200 day moving average price of $117.59. Gilead Sciences, Inc. has a fifty-two week low of $88.57 and a fifty-two week high of $128.70. The firm has a market cap of $150.25 billion, a PE ratio of 18.78, a price-to-earnings-growth ratio of 0.64 and a beta of 0.33. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. The company had revenue of $7.77 billion for the quarter, compared to the consensus estimate of $7.42 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. Gilead Sciences’s revenue was up 3.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th were paid a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.6%. The ex-dividend date of this dividend was Monday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently 48.99%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.